IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)          Journal is Currently Not Indexed in Scopus as on february 2021 list provided by scopus

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Evaluating Cardiac Safety of Trastuzumab in Iraqi Women with Breast Cancer

Author: BAHIR RAZZAQ, SABA RABEE ABDUL AZIZ, FATIMA THABET MOHSEN
Abstract: Trastuzumab,an immunotherapy which indicated for overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer disorders, with a risk of cardiac toxicity. This study was design to present the incidence of cardiac toxicity and its associated risk factors for breast cancer women receiving trastuzumab.This retrospective observational study enrolled 50 women with positive HER2 breast cancer who received trastuzumab in theBaghdad Oncology Centers, from August 2017 to March 2018. The incidence of cardiotoxicity and associated risk factors during treatment withtrastuzumab was evaluated. From 50 patient,18 (36%) exhibited cardiac complications, 12 % of them reduced their LVEF below 50%, 30% reduced their LVEF >10 points below their baseline, while 6% reduced their LVEF >15 points below their baseline.Of those 18, 8 patients (44.4%) stopping treatment because of drop in LVEF. In 7 of those patients, trastuzumab re-administered after normalization of EF values.Treatment course of trastuzumab was completed in 98% (49 patients), while2% (1 patient) required trastuzumab discontinuation definitively, as LVEF not recovered completely. Risk factors for cardiac toxicity included: patients elder than 65 years (p < 0.046), patients with low baseline LVEF (p < 0.027), those with concomitant and previous radiotherapy to the left side of the chest (p < 0.039), and those with elevated troponin levels at baseline (p < 0.034). In this study, trastuzumab-related cardiotoxicitywas comparable with that of literature data.This toxicityrepresented by asymptomatic LVEFreduction and less frequently symptomaticcardiac dysfunction. Most cases were transient and reversible.
Keyword: breast cancer; trastuzumab;cardiotoxicity;risk factors.
DOI: https://doi.org/10.31838/ijpr/2019.11.01.065
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free